Here's how you can reach us...
  • Tel:
  • Email:

Escherichia Coli Expression System-Based Therapeutic Protein Production

Inquiry

Escherichia coli (E. coli), the first host used for recombinant protein expression, has become a popular host choice due to its high yield, low cost, and ease of use. As a trusted protein production contract organization, CD Formulation is committed to expressing and producing therapeutic proteins in E. coli efficiently and economically. We provide one-stop services from codon optimization to recombinant protein expression and purification.

What is The E. coli Expression System?

E. coli is a well-known expression system. This system is favored for its rapid growth, simple culture conditions and low production costs, and is a powerful tool for producing various recombinant proteins in high yields. Typical expression strategies include the use of strong promoters and appropriate expression vectors to increase the expression level of the target protein. In this system, it is often necessary to optimize the induction conditions, culture temperature and nutrients to obtain high-purity and high-activity recombinant proteins. In addition, the E. coli expression system can also be combined with molecular biology techniques to achieve protein labeling, folding and purification, providing important tools and methods for biomedicine, drug development, and basic research.

Fig. 1 Cell-free protein expression system by using E. coli.Fig. 1 A simplified representation of cell-free protein expression system by using E. coli crude extract. (Pouresmaeil M, et al., 2023)

Explore Our E. coli Expression System-Based Therapeutic Protein Production Services

As a leading protein production contract organization, CD Formulation is focused on providing high-quality therapeutic protein production services to customers around the world. Our professional team has extensive experience in providing customized solutions for a wide range of biopharmaceutical products.

With our optimized E. coli expression system, we can efficiently produce high-purity recombinant proteins. Our customized workflows and options can meet the downstream applications of your products. Importantly, our team of scientists can help you solve various problems during protein purification.

Codon Optimization and Gene Synthesis (Optional)

Vector Construction

  • Clone cDNA into the appropriate expression vector.
  • Plasmid sequencing and bulk plasmid preparation.

Protein Expression Analysis

  • E. coli strain transformation.
  • Protein expression assessment (SDS-PAGE).

Expression and Purification

  • Small-scale expression, purification, and condition optimization.
  • QC analysis: SDS-PAGE, UV, etc.

Scalable Expression (Optional)

  • Protein refolding.
  • Soluble protein and inclusion body purification.
  • QC analysis: SDS-PAGE, UV, etc.

Large-scale Expression and Purification (Optional)

  • A large-scale expression and purification according to the selected appropriate expression conditions.
  • QC analysis: SDS-PAGE, UV, etc.

Target Protein Identification

  • Identify the protein using qualitative or quantitative analysis methods.
  • Purified proteins (can be lyophilized).

Features of E. coli Expression System

  • The growth cycle is short, and high cell density can usually be reached within a few hours, which is conducive to the rapid acquisition of large amounts of recombinant proteins.
  • Genetic manipulation is relatively simple, and the cloning, expression, and purification processes are easy to achieve.
  • The transformation efficiency of exogenous DNA is high, and the desired recombinant can be obtained with a high probability.
  • Unparalleled rapid growth kinetics.
  • Easy to culture, and expression conditions can be controlled.
  • High-level expression of various types of recombinant proteins, especially for small proteins and some easily soluble proteins.
  • Fast and simple transformation of exogenous DNA.

Our Different Expression Platforms for Therapeutic Protein Production

Expression Platform Properties
Growth Speed Expression Level Production Time Contamination Risk Posttranslational Modification
Protein Folding Phosphorylation Acetylation N-linked glycosulation O-linked glycosulation Acylation
Yeast Rapid Low-High Medium Low Sometimes Yes Yes High Mannitol Yes Yes
Baculovirus-Insect Cell Slow Low-High High High (e.g., virus) Suitable Yes Yes Simple Yes Yes
E. coli Rapid High Low Medium (e.g., endotoxin) Need No No No No No
Mammalian Cell Slow Low-Medium High Very high (e.g., virus, DNA) Suitable Yes Yes Complex Yes Yes

Why Choose Us for Therapeutic Protein Production Using E. coli Expression System?

  • Our team has extensive experience and a deep understanding of the E. coli expression system and excels in customizing expression and purification strategies to meet the specific requirements of your therapeutic protein, including post-translational modifications, solubility, and activity.
  • We have a proven track record in successfully producing complex therapeutic proteins.
  • We provide end-to-end services, including protein design, cloning, expression, purification, and characterization, ensuring comprehensive support throughout the project lifecycle.
  • We adhere to strict quality control measures throughout the production process to ensure compliance with regulatory standards.
  • We provide scalable therapeutic protein production solutions, from small-scale laboratory experiments to large-scale production for clinical trials and commercialization.
  • Our optimized protocols reduce production time, speed up the development process, and bring your product to market faster.

Publication

Published Data

Technology: E. coli Expression System

Journal: Int J Mol Sci.

IF: 4.9

Published: 2020

Results:

The authors present a cell-free (CF) system based on E. coli. This system enables the production of difficult-to-express protein/peptide molecules because the reaction medium can be adjusted and no supporting cell metabolism and viability are required. In addition, the optimization steps performed to develop a high-yield and cost-effective CF method are described, as well as the modifications of in vitro methods required for the production of difficult-to-obtain proteins.

Fig. 2 CF methodology for the production of diverse proteins.Fig. 2 Schematic representation of CF methodology modification for the production of diverse proteins. (Smolskaya S, et al., 2020)

Thanks to our in-house advanced E. coli expression platform, CD Formulation is committed to providing efficient and economical production of therapeutic proteins. Please don't hesitate to contact us if you are interested in our services. We look forward to cooperating with you.

References

  1. Kamionka M. Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol. 2011 Feb 1;12(2):268-74.
  2. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014 Apr 17;5:172.
  3. Kachhawaha K, Singh S, Joshi K, et al. Bioprocessing of recombinant proteins from Escherichia coli inclusion bodies: insights from structure-function relationship for novel applications. Prep Biochem Biotechnol. 2023;53(7):728-752.
  4. Smolskaya S, Logashina YA, Andreev YA. Escherichia coli Extract-Based Cell-Free Expression System as an Alternative for Difficult-to-Obtain Protein Biosynthesis. Int J Mol Sci. 2020 Jan 31;21(3):928.
How It Works
STEP 2
We'll email you to provide your quote and confirm order details if applicable.
STEP 3
Execute the project with real-time communication, and deliver the final report promptly.
Related Services

CD Formulation is an expert in formulation science and pharmaceutical process development in therapeutic proteins & peptides, dedicated to supporting biotherapeutics development and production...

Learn More

  • Tel:
  • Email:

Stay up to date with our latest releases of new research and promotions.

Copyright © CD Formulation. All Rights Reserved.